Theralase Technologies Inc. V.TLT

Six months from now...

[Eoganacht]

...we will get the 30 May 2024 MD&A.

Currently there are 4 patients at 360 days and 4 patients at 270 days. These 8 patients will all have had their 450 day assessment by May 30.

5 of these 8 patients have been CR since the beginning of the trial. If these 5 patients maintain their CR at 450 days we will be looking at a 450 day durable CR rate of 39%.

The other 3 patients could also conceivably end up CR as 2 of them are IR and could end up being reclassified as CR and 1 is already CR but only became CR as of their 360 day assessment. This patient might just hang on to their CR at their 450 day assessment. So if we get lucky and all 8 patients are CR at 450 days this will be a 450 day durable CR rate of 45%

I don't know if there are plans to present trial results at AUA and ASCO in 2024 but here are their dates.

ASCO Annual Meeting - May 31 - June 4, 2024 Chicago IL

AUA May 3 - May 6, 2024 San Antonio TX 

[Oilminerdeluxe]

But with these stellar numbers, we remain below 20 cents. What are we missing? There must be a reason or more.

[Eoganacht]

I think the current situation is because of the unexplained delays in submitting the BTD application. There are probably very good reasons for the delays, but retail shareholders have no access to this kind of behind-the-scenes information. Longterm investors may be willing to trust that Theralase management is doing what needs to be done but there is no reason for the market in general to have

[Oilminerdeluxe]

Thanks.